Although TP53 mutations occur in less than 10% of newly diagnosed AML patients, their incidence is 25% in elderly patients and 30% in patients with therapy-related AML/myelodysplastic syndrome (t-AML/MDS) [15–18]. This evidence concerns the gene TP53 and acute myeloid leukemia.